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Abstract
Background: High rates of typhoid fever in children in urban settings in Asia have led to focus on childhood
immunization in Asian cities, but not in Africa, where data, mostly from rural areas, have shown low disease incidence. We
set out to compare incidence of typhoid fever in a densely populated urban slum and a rural community in Kenya,
hypothesizing higher rates in the urban area, given crowding and suboptimal access to safe water, sanitation and
hygiene.
Methods: During 2007-9, we conducted population-based surveillance in Kibera, an urban informal settlement in Nairobi,
and in Lwak, a rural area in western Kenya. Participants had free access to study clinics; field workers visited their homes
biweekly to collect information about acute illnesses. In clinic, blood cultures were processed from patients with fever or
pneumonia. Crude and adjusted incidence rates were calculated.
Results: In the urban site, the overall crude incidence of Salmonella enterica serovar Typhi (S. Typhi) bacteremia was 247
cases per 100,000 person-years of observation (pyo) with highest rates in children 5–9 years old (596 per 100,000 pyo) and
2–4 years old (521 per 100,000 pyo). Crude overall incidence in Lwak was 29 cases per 100,000 pyo with low rates in children
2–4 and 5–9 years old (28 and 18 cases per 100,000 pyo, respectively). Adjusted incidence rates were highest in 2–4 year old
urban children (2,243 per 100,000 pyo) which were .15-fold higher than rates in the rural site for the same age group.
Nearly 75% of S. Typhi isolates were multi-drug resistant.
Conclusions: This systematic urban slum and rural comparison showed dramatically higher typhoid incidence among urban
children ,10 years old with rates similar to those from Asian urban slums. The findings have potential policy implications
for use of typhoid vaccines in increasingly urban Africa.
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Introduction
With improvements in municipal drinking water treatment,
sanitation, hygiene, and food production and preparation, illness
and death from typhoid fever, once rampant in New York,
London and other Western cities in the late 18009s [1–3],
became rare in industrialized nations during the 20
th Century
[2–4]. By contrast, well into the 21
st Century, typhoid remains a
problem in lesser developed countries [5]. Most recent focus on
typhoid disease burden has been on Asian urban centers, where
high incidence rates have been documented within urban slums
[5,6]. However, little attention has been paid to typhoid
prevention in Africa, where there have been few systematic
investigations, and where a recent study from a rural area
showed low incidence [7].
Since 2006, we have collected population-based surveillance data
for infectious disease syndromes in an urban informal settlement and
from a rural area in Kenya to provide data for use in characterizing
emerging pathogens, estimating disease burden, defining priorities
for public health research and interventions, and for sites to evaluate
the impact of new interventions [8,9]. We set out to compare
incidence of Salmonella enterica serovar Typhi (S. Typhi) bacteremia in
a densely populated urban slum and a rural community in Kenya,
hypothesizing higher rates in the urban area, given crowding and
suboptimal access to safe water, sanitation and hygiene and the high
rates within urban settings in Asia with similar characteristics.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29119Methods
The Kenya Medical Research Institute-Centers for Disease
Control and Prevention collaboration (KEMRI-CDC) has con-
ducted active population-based surveillance for febrile illness,
pneumonia, diarrheal disease and jaundice within two of 12
neighborhoods or ‘‘villages’’ in Kibera, Nairobi, Kenya and in
Lwak in rural western Kenya within a district currently known as
Rarieda in Nyanza Province, since October 2005 (Figure 1). The
Kibera surveillance area is 0.40 km
2 and includes approximately
28,000 participants of all ages (71,000 people/km
2). In Lwak the
surveillance area is 100 km
2 and there are approximately 25,000
participants of all ages (325 people/km
2). Consenting households
(,1% of heads of households refused to participate) were visited
every 2 weeks by community interviewers who collected
standardized information into pre-programmed personal data
assistants (PDA) about illnesses in residents and healthcare-seeking
associated with that illness, as described in detail previously [8,9].
An existing clinic, known as the Tabitha Clinic, operated by
Carolina for Kibera, was enhanced to serve as the Kibera site field
clinic, and 6 clinicians (medical officers and clinical officers) and 7
nurses were hired and trained on standard medical practices,
including treatment algorithms and on surveillance and diagnostic
criteria according to the study protocol. We also hired a clinical
officer and 2 nurses to work with existing health care providers at
Lwak Mission Hospital which serves as the Lwak field clinic.
Specimens tested for this study were only collected at the field
clinics; no specimens were collected during home visits.
The clinical component of the surveillance system has been
described [9]. Briefly, participants were allowed free access to the
two study clinics, Tabitha (Kibera) and Lwak Mission Hospital
(Lwak), for any acute medical condition, were clinically assessed,
and provided with medications and follow-up without charge; data
were systematically collected for all patients at both sites [9].
During home visits, community interviewers encouraged ill
participants to visit the field clinic; however, no financial
incentives, travel reimbursements, or direct transport were
provided. Clinicians used their clinical judgment when deciding
whether to treat empirically with an antimicrobial drug before
blood culture results were available. Study team members went to
homes of patients from whom S. Typhi was isolated from blood
culture and asked them to return to clinic where empirical therapy
Figure 1. Map of Kenya with Insets Showing Location of Study Sites.
doi:10.1371/journal.pone.0029119.g001
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either ciprofloxacin or ceftriaxone; very ill patients were referred
to Mbagathi Hospital.
Blood cultures (one per patient) were obtained from patients
who met respiratory and febrile illness case definitions (see below)
(Figures 2a and 2b). Malaria smears were collected at the
discretion of clinicians. Also, in Lwak, all patients who were
hospitalized (except for reasons that were obviously not related to
infection, like trauma) underwent blood culture before being given
antimicrobial drugs. In some cases, clinicians in both sites ordered
a blood culture from patients who did not meet fever or respiratory
criteria if they had clinical suspicion of sepsis. Written informed
consent was collected for all participants involved in this study. In
Kibera, febrile illness was defined as a documented axillary
temperature of $38.5
oC until November 1, 2008, when the
threshold was decreased to $38.0
oC. For the entire study period
in Lwak, febrile illness was defined as a temperature $38.0
oC. In
Kibera, all consenting patients with febrile illness were offered
blood culture. In Lwak, because of a higher expected incidence of
febrile illness due to malaria, blood cultures were collected each
day from only the first two persons$5 years old and the first two
children ,5 years old. Respiratory illness was defined for children
,5 years old as: cough OR difficulty breathing AND one of
the following: convulsions, unable to drink fluids or unable to
breastfeed, lethargic, chest indrawing, vomiting everything,
stridor, oxygen saturation ,90%; and for persons $5 years old
as cough OR difficulty breathing OR chest pain AND one of the
following: temperature $38.0
oC and oxygen saturation ,90%.
For children #5 years of age, 1–3 mL of blood was collected
and placed into a BACTEC Ped Plus/F (enriched Soybean-casein
digest broth with CO2; Becton-Dickenson) blood culture bottle.
For participants .5 years old, we attempted to collect 8–10 mL of
blood, which was placed into a BACTEC Plus/F (for adults)
bottle. We processed blood cultures when amount of blood
collected was less than the desired volume (majority of specimens);
however, isolation rates did not vary by volume of blood cultured
(data not shown).
Blood culture bottles from Kibera were incubated in a Bactec
9050 system at the KEMRI-CDC laboratory in Nairobi. Bottles
signaling positive from Kibera were sent by overnight mail to the
KEMRI-CDC laboratory in Kisumu. Bottles collected in Lwak
were also placed in a BACTEC 9050 system at the Kisumu
KEMRI-CDC laboratory. Subcultures were processed using
standard microbiological procedures [10]. Salmonella isolates were
identified and confirmed using an API 20E system (Appareils et
Procedes d’Identification, Montalieu Vercieu, France) following
manufacturers’ instructions. Commercial agglutinating antiserum
(Denka Seiken, Tokyo, Japan) was used to serotype the Salmonella
isolates [10]. Antimicrobial susceptibility testing was performed on
Salmonella isolates by Kirby-Bauer disc diffusion [11] and for the
purposes of this report, interpreted according to the latest Clinical
and Laboratory Standards Institute guidelines [12]. Multi-drug
resistant S. Typhi was defined by resistance to chloramphenicol,
ampicillin and trimethoprim [13,14].
For the home visits, data were collected by trained community
interviewers on pre-programmed personal digital assistants (PDA)
with drop-down response menus and validation checks pro-
grammed in Microsoft Visual Studio.Net 2005. Kibera clinical
data were entered into a customized computer-based health care
information system, developed by GFL Information, Nairobi,
Kenya. In Lwak, clinical data were entered onto teleforms,
standardized for this project (with the same fields used as the
Kibera computer-based system), and scanned and reviewed by
data clerks for accuracy and completeness. Statistical analysis was
performed using SAS system for Windows (SAS Institute, Cary,
NC) version 9.1.
Blood culture collection and processing began in March 2007 in
Kibera and in October 2006 in Lwak. We analyzed data from
Kibera for March 1, 2007- February 28, 2009 and from October
1, 2006 to September 30, 2009 for Lwak.
Overall and age-group incidence rates were calculated by
dividing number of cases of S, Typhi bacteremia by number of
person-years of observation (pyo); permanent residence status on
enrolled participants in surveillance areas was used to determine
start and stop dates for person-time contribution for each
participant [9]. Start date was either the date that the study period
began for those residents leaving in the surveillance area at the time
the study began, or the date at which a new resident (an ‘‘in-
migrant’’) had completed documented residence (as determined by
community interviewers) within the study area for a period 4
months (8 biweekly home visits by community interviewers). Stop
date was either the end of the study period or the date that a
participant moved away from the study area (out-migrant), as
determined during home visits by community interviewers. The
period between start and stop dates for each resident (in days) was
divided by 365.25 to determine pyo, which was then totaled for all
participants (or all participants within defined age groups). We
calculated age-adjusted incidence rates to account for cases of S.
Typhi bacteremia missed. We made two age group-specific
adjustments. The first adjustment (Adjustment #1) was based on
patients who visitedthestudyclinicanddidnot have a bloodculture
done, despite meeting fever and respiratory case definitions—this
took into account that in Lwak only the first two children ,5a n d
the first two participants $5 years old with documented fever
underwentblood culture—theadjustment putthenumberofpeople
who met surveillance criteria for blood culture in the denominator
and the number of patients who actually had blood culture done in
the numerator; we divided number of participants with febrile
illnesscriteria and ALRI criteria who had blood culture obtained by
number of all surveillance participants presenting to study clinic
meeting those criteria. The principal reasons in Kibera for not
having a blood culture obtained were that phlebotomy was
unsuccessful or that patient/caretaker did not want to wait
additional time. The resulting proportions were divided into crude
incidence rates. The second extrapolation (Adjustment #2) was
based on number of patients whose indication for blood culture was
either febrile illness or ALRI, based on data from the home visit,
who visited a clinic, but not the study clinic, and, thus, did not have
the opportunity for blood culture, since no other clinics in either
area performed them. We assumed that patients meeting illness
criteria who visited another clinic in the area were no different than
those that visited the study clinic in likelihood of having typhoid
fever. Thus, we divided number of residents (within each age-group
category) withhistoryoffeverorALRIonhomevisitwhovisitedthe
study clinic by number of residents with history of fever who visited
any clinic for that illness. Episodes of fever not associated with visits
to any clinic were not ‘‘counted’’ in the adjustment. This proportion
was divided into the rate Adjustment #1 figure for each age group;
the result represented final age-specific adjusted rates (Adjustment
# 2). Exact 95% confidence intervals were calculated for the
unadjusted incidence rates except when the number of cases was 0.
Ninety-five percent confidence intervals were calculated for the
adjusted incidence rates by adjusting the lower and upper ends of
the exact 95% confidence intervals for the unadjusted rates
accordingly.
The protocol was reviewed and approved by the Ethical Review
Committee at the Kenya Medical Research Institute and the
Institutional Review Board of CDC-Atlanta.
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S. Typhi was isolated from 137 (6.4%) of 2,142 blood cultures
processed from Kibera (during the 2-year study period) (Table 1)
and from 22 (0.6%) of 3,577 blood cultures from rural Lwak
(during the 3-year study period). S. Typhi was isolated twice from
blood cultures collected from two patients within a 7-day period in
Kibera, which we categorized as persistent bacteremia in single
cases of typhoid illness, leaving 135 discrete cases of bacteremia in
Kibera. The overall contamination rate of blood cultures was
7.4%; S Typhi was not isolated from any blood culture from which
a contaminant was grown.
Figure 2. a) Flow Chart showing Numbers of Enrollees from Lwak, Blood Cultures Processed and Pathogens Isolated, Including S Typhi, Isolated.
b) Flow Chart showing Numbers of Enrollees from Kibera, Blood Cultures Processed and Pathogens Isolated, Including S Typhi, Isolated.
doi:10.1371/journal.pone.0029119.g002
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among 10–17 year olds, followed by 5–9 year olds (11%) (Table 1).
Of the 135 cases in Kibera, 51 (37.8%) had blood cultures
collected because they met the case definition for acute respiratory
infection. There were no deaths within 30 days of onset of illness
and 2 (1.5%) patients were hospitalized.
In contrast to the urban and rural differences for isolation of S.
Typhi, non-typhoidal Salmonella (Salmonella Enteritidis and Salmo-
nella Typhimurium) were isolated from a much higher proportion
of cultures from Lwak, when compared with Kibera (1.6% versus
0.3%;p,0.0001). Salmonella Paratyphi was not isolated from any
blood cultures.
The crude incidence of blood culture-confirmed typhoid fever
in Kibera was 247 cases per 100,000 pyo compared with 29 cases
per 100,000 pyo in Lwak. The crude rates in Kibera were highest
in children 5-to-9 and 2-to-4 years old (596 and 521 cases per
100,000 pyo, respectively) (Table 2); by contrast, the highest rates
in Lwak were in the 18–34 year age group (63 cases per 100,000
pyo) with very low rates in children 2–4 and 5–9 years old (28 and
18 cases per 100,000 pyo, respectively) (Table 3).
The overall adjusted incidence rate for S. Typhi bacteremia in
Kibera was 843 cases per 100,000 pyo (Table 2). The adjusted
incidence rates in the 2-to-4 and 5-to-9 year age groups in Kibera
were 17-fold and 22-fold higher than the adjusted rates for the
respective age groups in Lwak (Table 3).
Cases occurred throughout the study period in Kibera with no
clear seasonality (Figure 3). While rainfall patterns did not
correlate (using Pearson correlation coefficient) with disease
incidence in general (r=20.31, p=0.14), the peak months for
cases, April 2008 and October 2007, followed months with peak
rainfall by 1-to-2 months (Figure 3). However, other peak rainfall
months, like April 2007 and November 2008 were not followed by
an increase in cases. Cases in Kibera occurred throughout all 10
pre-determined geographic zones within the study area with zonal
incidence rates not differing significantly (data not shown).
Most isolates of S. Typhi were resistant to chloramphenicol and
ampicillin. (Table 4). While all isolates were susceptible to
ciprofloxacin, 7% of strains had decreased susceptibility (3.2%
were fully resistant) to nalidixic acid. Nearly all isolates were
susceptible to ceftriaxone (Table 4); overall, 77.8% of isolates were
multi-drug resistant. The proportions of susceptible isolates for
each antimicrobial drug were similar regardless of age group (data
not shown).
Self-reported or proxy information from the biweekly home
visits in Kibera and Lwak was available for 79 (56%) of 141 cases
with fever reported. Duration of fever ranged from 2–36 days
(mean= 10.4 days; 95% CI=8.7–12 days; median=8 days).
Based on data collected during study clinic visit for 116 patients
with S. Typhi bacteremia seen at Kibera or Lwak, a variety of
symptoms, especially fever (89%), cough (49%), headache (29%),
diarrhea (21%) and chills (20%), were more likely to be seen in
patients with S. Typhi bacteremia than in patients from whom S.
Typhi was not isolated; however, abdominal pain was the only
symptom differentiating patients with S. Typhi bacteremia from
other bacteremic patients. (Table 5).
Discussion
Our findings, the first population-based study from an urban
slum in Africa, suggested very high rates of bacteremic typhoid
Table 1. Isolation rates for S. Typhi from blood cultures collected in Kibera and Lwak.
Age
S. Typhi isolates
(Column % by age)
Any pathogen isolated
(Row % S. Typhi*)
Blood cultures done
(Row % S.Typhi**)
A. KIBERA
,2 years 3 (2%) 17 (18%) 353 (0.8%)
2–4 years 32 (24%) 52 (62%) 677 (4.7%)
5–9 years 48 (36%) 71 (68%) 454 (10.6%)
10–17 years 24 (18%) 31 (77%) 189 (12.7%)
18–34 years 25 (19%) 45 (56%) 341 (7.3%)
35–49 years 2 (2%) 37 (5%) 106 (1.9%)
$50 years 1 (1%) 2 (50%) 22 (4.5%)
Total 135
& 225 (60%) 2142 (6.3%)
B. LWAK
,2 years 1 (5%) 36 (3%) 758 (0.1%)
2–4 years 2 (9%) 33 (6%) 1018 (0.2%)
5–9 years 2 (9%) 20 (10%) 770 (0.3%)
10–17 years 4 (18%) 16 (25%) 402 (1.0%)
18–34 years 11 (50%) 57 (19%) 447 (2.5%)
35–49 years 0 (0%) 26 (0%) 244 (0.0%)
$50 years 2 (9%) 25 (8%) 196 (1.0%)
Total 22 213 (10%) 3835 (0.6%)
*Proportion of pathogens isolated that were S. Typhi by age group.
**Proportion of blood cultures done from which S. Typhi was isolated.
&Two patients had S. Typhi isolated from blood cultures twice during a seven day period (representing persistent bacteremia); for the purposes of these rate
calculations, we excluded one of the blood cultures for each of these patients. We did not have age information for one of the patients.
doi:10.1371/journal.pone.0029119.t001
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slums in several Asian settings, including Kolkata, Jakarta,
Karachi and Dhaka, where rates per 100,000 children per year
in children 2–4 years of age were 340, 149, 573, and 1,870,
respectively [15,16]. It is likely that because of dense population
and severely limited options for sanitation and safe water, people
living within urban slums in Africa and in Asia, are at higher risk
for typhoid fever. The findings suggest that prevention efforts,
including immunization programs, should, at minimum, target
impoverished urban slums.
Typhoid fever is estimated to occur annually in .20 million
people worldwide [5]. With 1–4% mortality from invasive S.
Typhi infection, the annual number of deaths is estimated to be
200,000-to-800,000 globally [5,17]. Global estimates have as-
sumed that most of the disease burden is in Asia [5], but only three
vaccine trials and no population-based studies from Africa were
available for inclusion in the estimates. In recommending use of
typhoid vaccine in school age or preschool children in geographic
areas of known high incidence, especially urban centers in Asia,
WHO called for more epidemiologic data from Africa to inform
recommendations for that continent [6]. Our findings suggest very
high incidence in a densely populated urban slum and low
incidence in a rural area. In addition, three population-based
studies from rural sites in Africa have reported exceedingly low
incidence of typhoid fever [7,18,19]; however, there are clearly
complexities in the epidemiology beyond current understanding.
S. Typhi can be an important pathogen in rural or peri-urban
areas, as shown recently in hospital-based studies in Tanzania,
Ghana [20–22], and during recent outbreaks of typhoid fever in
rural areas in Malawi and Uganda [23,24]. The differences we
observed between the rural and urban sites were not likely due to
differences in HIV seroprevalence rates (16–18% in both areas;
CDC unpublished data).
In the 19809s, high rates (661 cases per 100,000 children per
year) of bacteremic typhoid fever were suggested in children, 5-
to-16 years old, extrapolating incidence data from two
unvaccinated groups (representing vaccine trial and non-vaccine
trial participants under blood culture surveillance) during a
typhoid vaccine trial in a peri-urban township in the Eastern
Tranvaal of South Africa [25]. A hospital-based study from
urban Kigali, Rwanda during the same decade showed that S.
Typhi was by far the most commonly isolated pathogen [5.2%]
from blood cultures of 900 consecutive febrile children [26]. By
contrast, a hospital-based study conducted in the late 19909si n
Blantyre, Malawi found very few S.T y p h ib a c t e r e m i a si n
children, while reporting frequent isolation of non-typhoidal
salmonellae in a malaria endemic area; however, the living
conditions for patients residing within the hospital catchment
area were not described [27].
The urban population in sub-Saharan Africa is expected to
double to nearly 800 million people by 2030 [28]. Infrastructure
has not kept pace with massive urban in-migration, resulting in
expansion and creation of urban slums, creating a variety of public
health challenges and the potential for catastrophic epidemics
[29], and increasing rates of diseases linked to water, sanitation
and hygiene infrastructure, like typhoid fever.
Table 2. Crude and Adjusted Rates of S Typhi Bacteremia in Kibera.
Age
in years Syndrome
S.typhi
(n) Pyo*
Crude Rate per
100,000
pyo % cultured
Rate,
Extrapolation
1**(Extrapolated
No. of typhi cases)
% clinic
visits to
Tabitha
Adjusted Rate
Extrapolation
2***(95% CI)
0–1 Overall
SARI Outpatient
Fever, not SARI
3
2
1
3,457 86.8
57.9
28.9
14.0
21.0
549.6(19)
405.0(14)
144.6(5)
66.9 821.5
(265–2547)
2–4 Overall
SARI Outpatient
Fever, not SARI
32
9
23
6,138 521.3
146.6
374.7
41.0
35.2
1,417.3(87)
358.4(22)
1,058.9(65)
63.2 2,242.6
(1586–3171)
5–9 Overall
SARI Outpatient
Fever, not SARI
48
26
22
8,049 596.3
323.0
273.3
65.2
38.4
1,205.1(97)
496.9(40)
708.1(57)
67.4 1,788.0
(1348–2373)
10–17 Overall
SARI Outpatient
Fever, not SARI
Others
24
5
18
1
8,017 299.4
62.4
224.5
12.5
65.5
43.83
623.7(50)
99.8(8)
511.4(41)
12.5(1)
71.7 869.9
(583–1298)
18–34 Overall
SARI Outpatient
Fever, not SARI
Others
25
9
15
1
20,309 123.1
44.3
73.9
4.9
65.1
57.0
201.9(41)
68.9(14)
128.0(26)
4.9(1)
64.7 312.1
(211–462)
35–49 Overall
SARI Outpatient
Fever, not SARI
2
0
2
6,443 31.0
0.0
31.0
80.0
47.2
62.1(4)
0.0(0)
62.1(4)
62.1 100.0
(25–400)
.50 Overall
SARI Outpatient
Fever, not SARI
1
1
0
2,120 47.2
47.2
0.0
73.3
100.0
47.2(1)
47.2(1)
0.0(0)
70.9 66.6
(13–644)
.17 Overall
SARI Outpatient
Fever, not SARI
Others
28
10
17
1
28,872 97.0
34.6
58.9
3.5
56.4
68.7
152.4(44)
62.3(18)
86.6(25)
3.5(1)
64.5 231.3
(160–335)
Overall 135 54,535 247.5 548.3(299) 66.7 822.0 (695–973)
doi:10.1371/journal.pone.0029119.t002
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school-age children are at much higher risk than children ,5
years of age [30], our data are consistent with recent data from
Asian urban settings where incidence of typhoid fever in younger
(pre-school) children (2-to-4 years old) is on par with that for
children 5-to- 9 years old [15,16].
If validated in other urban settings in Africa, the findings from
our study would support typhoid immunization of young children
with a geographically and environmentally targeted approach for
immunization programs, representing a departure from universal
immunization strategies that tend to immunize all children in a
region regardless of specific location of residence. During the past
two decades, new vaccines have become available to prevent high
impact illnesses like Haemophilus influenzae B disease, pneumococcal
disease, hepatitis B, meningococcal meningitis, and rotavirus
diarrhea. During the same period, two vaccines for typhoid fever
(oral Ty21a, licensed in 1983 and parenterally administered Vi
polysaccharide vaccine, licensed in 1994) have been available, but
are used almost exclusively by persons from wealthy countries,
including military personnel, who travel to the developing world.
Newer typhoid vaccines, including conjugated Vi polysaccha-
ride vaccines and single-dose liquid oral formulations, still in
development phase [31–33], would be attractive because they
could be given to infants as part of routine infant immunization
programs and protect children through high incidence ages. As
with what transpired in industrialized urban centers at the turn of
the twentieth century, dramatic improvements in provision of safe
water and sanitation would likely substantially diminish the burden
of diseases like typhoid, especially in Kibera and similar settings.
Typhoid immunization program implementation would not be
straightforward since current vaccines could not be given as part of
the routine infant immunization program.
High vaccination rates would likely dramatically reduce the
incidence of typhoid fever in urban slum environments, especially
in combination with safer water, sanitation and hygiene.
Ultimately, the impact on incidence of significant febrile and
respiratory illness, hospitalizations and death of a typhoid
immunization program could best be evaluated in large demon-
stration ‘‘vaccine probe’’ projects where interventions are
selectively applied in cluster-randomized or sectioned urban slum
Table 3. Crude and Adjusted Rates of S Typhi Bacteremia in Lwak.
Age
in years Syndrome
S. typhi
(n) Pyo*
Crude Rate
per
100,000
pyo % cultured
Rate
Extrapolation
1**(Extrapolated
No. of typhi cases)
% clinic
visits to
Lwak
Adjusted Rate
Extrapolation
2***(95% CI)
0–1 Overall
SARI
Fever
a
Inpatient
b
1
1
0
0
6544.5 15.3
15.3
19.8
22.2
31.7
76.0(5)
76.0(5)
22.0 345.7 (43–2158)
2–4 Overall
SARI
Fever
Inpatient
2
1
1
0
7027.54 28.5
14.2
14.2
24.6
28.4
41.4
156.5 (11)
99.6 (7)
56.9(4)
21.1 742.6 (113–1804)
5–9 Overall
SARI
Fever
Inpatient
2
2
0
0
11312.0 17.7
17.7
0
0
49.5
35.7
47.6
35.4(4)
35.4(4)
16.4 215.5 (56–903)
10–17 Overall
SARI
Fever
Inpatient
4
3
0
1
16756.5 23.9
17.9
0
6.0
48.3
33.3
41.5
47.8(8)
35.8(6)
0
11.9(2)
18.3 260.4 (108–767)
18–34 Overall
SARI
Fever
Inpatient
11
2
5
4
17359.5 63.4
11.5
28.8
23.0
63.6
43.5
40.6
144.0(25)
17.3(3)
69.1(12)
57.6(10)
17.7 815.7(339–1106)
35–49 Overall
SARI
Fever
Inpatient
0
0
0
0
7655.1 0 61.2
50.0
32.8
0 14.5 0.0
.50 Overall
SARI
Fever
Inpatient
2
1
0
1
10362.0 19.3
9.7
0
9.7
60.1
38.9
34.2
48.3(5)
19.3(2)
0
29.0(3)
8.5 565.8(119–1896)
.17 Overall
SARI
Fever
Inpatient
13
3
5
5
35376.6 37.8
8.7
14.5
14.5
62.2
44.5
36.3
84.8(30)
14.1(5)
31.1(11)
39.6(14)
13.6 625.6(290–860)
Overall 22 77017.0 28.6 75.3(58) 16.9 445.0 (308–711)
*pyo – person years of observation.
**Extrapolation 1 accounts for patients meeting case definitions for blood culture in Tabitha clinic who did not have blood cultures done.
*Extrapolation 2 uses the rates for extrapolation 1 and extrapolates further by accounting for the % of persons at the biweekly home visit with SARI or fever for more
than 2 days who go to a clinic other than the field clinics:Tabitha (Kibera) or Lwak Mission Hospital (Lwak).
doi:10.1371/journal.pone.0029119.t003
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intervention and non-intervention areas.
We found that circulating S. Typhi strains were resistant to
commonly used antimicrobial drugs, and that 7% of strains had
decreased susceptibility to nalidixic acid, suggesting that high
levels of fluoroquinolone resistance may soon follow, as has
occurred in India and elsewhere [14,34]. Emergence of ciproflox-
acin-resistant of S. Typhi will likely increase illness duration,
proportion of treatment failures, and cost of treatment, adding to
burden of typhoid fever, further highlighting the urgency of
implementing effective typhoid immunization programs in target-
ed settings [5].
A key limitation for this study was that we found very few cases
of severe typhoid illness . While intensive surveillance enabled
early detection of cases and provided reliable data for adjusting
rates, severe disease and poor outcomes were likely averted
because study clinics provided high standards of care in areas
where health care options are typically limited [35]. Furthermore,
the relatively small population limited ability to detect severe
disease and death, which tend to occur in a minority of cases. Our
active surveillance methods may have also detected self-limited
disease, of relatively low public health consequence (though such
patients would likely be able to transmit disease to other
susceptible people). While the crude rates were as high as those
reported from urban sites in Asia, we relied on our active
household surveillance to provide one of two adjustment factors.
The adjustments depend upon similarities in clinical severity for
those who were cultured versus those who were not, which we
assumed, but cannot prove. We did not adjust for limited
sensitivity of blood cultures (between 30–70%, depending upon
volume of blood cultured and presence of antibiotics) [36–38], or
for the rate of contamination of blood cultures of 7.4%, which as a
consequence underestimated the burden of disease. Some of these
weaknesses could be addressed partially through hospital-based
surveillance in parallel with community/population-based data
[35] and via a vaccine probe study, as mentioned above.
Using adjusted incidence rates and recent census data [39], we
estimate just over 100,000 cases of typhoid fever per year from
urban slums in Kenya. Among children 2–9 years old living in
informal settlements, there are an estimated 32,000 cases of
typhoid fever annually. Targeting these children with a typhoid
immunization campaign, assuming vaccine efficacy of 60%
(estimates of effectiveness range from 50% to 80% depending
upon vaccine and setting [40,41], and 70% vaccination rates
(likely achievable in campaigns in densely populated settings),
would prevent approximately 13,500 cases/year of typhoid fever
in vaccinated children. In addition, indirect protection would
likely reduce transmission from children to other household
members or other contacts, as was recently demonstrated in a
typhoid vaccine effectiveness study in Kolkata [41].
Failure to recognize and act on typhoid burden and potential
for its prevention adds another dimension to currently neglected
tropical diseases in urban African settings [42] for which safe and
effective prevention options are already available, but are not used.
Figure 3. Number of Cases of Typhoid fever and Rainfall Accumulation per Month, Kibera.
doi:10.1371/journal.pone.0029119.g003
Table 4. S. Typhi isolates susceptible to a variety of
antimicrobial drugs--Kibera and Lwak.
Drug
Kibera (n=135)
n( % )
Lwak (n=22)
n( % )
Total (n=157)
n( % )
Ampicillin 25 (19.1%)
b 7 (31.8%) 36 (22.9%)
b
Ceftriaxone 129 (98.5%)
b 21 (95.5%) 150 (98.7%)
b
chloramphenicol 23 (17.4%)
a 8 (36.4%) 31 (20.1%)
a
ciprofloxacin 130 (98.5%)
a 22 (100%) 152 (98.7%)
a
cotrimoxazole 23 (17.4%)
a 7 (31.8%) 30 (19.5%)
a
naladixic acid 123 (93.2%)
a 21 (95.5%) 144 (93.5%)
a
a: test not done for 3 isolates.
b: tests not done for 4 isolates.
doi:10.1371/journal.pone.0029119.t004
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will become more critically urgent.
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